Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on June 5, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 80.7% quorum; 48,509,906 of 60,135,062 eligible shares represented.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 80.7% quorum; 48,509,906 of 60,135,062 eligible shares represented
- Richard W. Dugan, Charles C. Duncan, Ph.D., and Anne Sempowski Ward elected through 2029
- PwC ratified as independent auditor for fiscal year ending December 31, 2026, with 48,103,698 votes supporting
- Executive compensation approved on a non-binding advisory basis, with 35,242,659 votes supporting
- 2016 Equity Incentive Plan amendment approved, increasing authorized shares available for issuance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.